Skip to main content
Show full summary

Lord Mendelsohn to ask His Majesty's Government whether the COVID-19 monoclonal antibody Evusheld 2.0 is being treated as a priority for assessment; and whether they have any plans to rollout a programme to be fast-tracked to vulnerable patients.  HL3257

Question HL3257: tabled on 13 March 2024 and due for answer by 27 March 2024

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Mendelsohn to ask His Majesty's Government whether the COVID-19 monoclonal antibody Evusheld 2.0 is being treated as a priority for assessment; and whether they have any plans to rollout a programme to be fast-tracked to vulnerable patients.  HL3257
Legend for business item text
Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.